References for Chapter 18
Antiplatelet and Other Antithrombotic Drugs

William H. Frishman, MD
Robert G. Lerner, MD
Harit Desai, MD


82. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329, 1996.
95. Hanjis C, Frishman WH, Lerner RG: Aspirin resis-
References to Chapter 18


119. Taniuchi M, Kurz HI, Lasala JM: Randomized


References to Chapter 18


160b. Wiviott SD, Mega JL: Another step on the road to...
180. O’Donoghue M, Antman EM, Braunwald E, et al: The efficacy and safety of prasugrel with and with-


18-10  Cardiovascular Pharmacotherapeutics


236. van’t Hof AWJ, Valgimigli M: Defining the role of platelet glycoprotein receptor inhibitors in STEMI. Focus on tirofiban. Drugs 69; 85, 2009.


341. Jones A, Geczy CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunol-
domized double-blind comparison of two doses of Hirulog or heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132, 1995.


380. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA


398a. Ozer N, Cam N, Tanyurek B, et al: The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose re-


454. Meadows TA, Bhatt DL: Clinical aspects of platelet inhibitors and thrombus formation. *Circ Res* 100:


References to Chapter 18


522a. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators: Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. *Am Heart J* 159: 340, 2010.


References to Chapter 18


